These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21651400)

  • 1. Olmesartan, microalbuminuria, and type 2 diabetes.
    Fioretto P; Mauer M
    N Engl J Med; 2011 Jun; 364(23):2260-1; author reply 2262-3. PubMed ID: 21651400
    [No Abstract]   [Full Text] [Related]  

  • 2. Olmesartan, microalbuminuria, and type 2 diabetes.
    Lammert A; Krämer BK; Krüger B
    N Engl J Med; 2011 Jun; 364(23):2261; author reply 2262-3. PubMed ID: 21651399
    [No Abstract]   [Full Text] [Related]  

  • 3. Olmesartan, microalbuminuria, and type 2 diabetes.
    Yudkin JS; Lehman R
    N Engl J Med; 2011 Jun; 364(23):2260; author reply 2262-3. PubMed ID: 21651401
    [No Abstract]   [Full Text] [Related]  

  • 4. Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.
    Ingelfinger JR
    N Engl J Med; 2011 Mar; 364(10):970-1. PubMed ID: 21388316
    [No Abstract]   [Full Text] [Related]  

  • 5. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
    Haller H; Ito S; Izzo JL; Januszewicz A; Katayama S; Menne J; Mimran A; Rabelink TJ; Ritz E; Ruilope LM; Rump LC; Viberti G;
    N Engl J Med; 2011 Mar; 364(10):907-17. PubMed ID: 21388309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Haller H; Viberti GC; Mimran A; Remuzzi G; Rabelink AJ; Ritz E; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Januszewicz A
    J Hypertens; 2006 Feb; 24(2):403-8. PubMed ID: 16508590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olmesartan, microalbuminuria, and type 2 diabetes.
    Farmakis D; Aessopos A
    N Engl J Med; 2011 Jun; 364(23):2261-2; author reply 2262-3. PubMed ID: 21651398
    [No Abstract]   [Full Text] [Related]  

  • 8. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.
    Menne J; Ritz E; Ruilope LM; Chatzikyrkou C; Viberti G; Haller H
    J Am Heart Assoc; 2014; 3(2):e000810. PubMed ID: 24772521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
    Sofue T; Kiyomoto H; Kobori H; Urushihara M; Nishijima Y; Kaifu K; Hara T; Matsumoto S; Ichimura A; Ohsaki H; Hitomi H; Kawachi H; Hayden MR; Whaley-Connell A; Sowers JR; Ito S; Kohno M; Nishiyama A
    Am J Hypertens; 2012 May; 25(5):604-11. PubMed ID: 22318512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Ritz E; Viberti GC; Ruilope LM; Rabelink AJ; Izzo JL; Katayama S; Ito S; Mimran A; Menne J; Rump LC; Januszewicz A; Haller H
    Diabetologia; 2010 Jan; 53(1):49-57. PubMed ID: 19876613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
    Ikeda H; Hamamoto Y; Honjo S; Nabe K; Wada Y; Koshiyama H
    Diabetes Res Clin Pract; 2009 Jan; 83(1):117-8. PubMed ID: 19062123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?
    Consuegra-Sánchez L; Sanchis J; Núñez J; Cascón JD; Villegas M; Picó F
    Rev Esp Cardiol (Engl Ed); 2012 Apr; 65(4):378-80. PubMed ID: 21840109
    [No Abstract]   [Full Text] [Related]  

  • 13. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.
    Menne J; Izzo JL; Ito S; Januszewicz A; Katayama S; Chatzykirkou C; Mimran A; Rabelink TJ; Ritz E; Ruilope LM; Rump LC; Viberti G; Haller H;
    J Hypertens; 2012 Apr; 30(4):811-8; discussion 818. PubMed ID: 22418908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes: ROADMAP: the road to renoprotection?
    Roscioni SS; Heerspink HJ; de Zeeuw D
    Nat Rev Nephrol; 2011 May; 7(8):427-8. PubMed ID: 21610679
    [No Abstract]   [Full Text] [Related]  

  • 16. Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.
    Chatzikyrkou C; Menne J
    Expert Rev Cardiovasc Ther; 2012 Sep; 10(9):1087-92. PubMed ID: 23098143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of gender on transition of normo- to microalbuminuria under angiotensin receptor blocker therapy in diabetes.
    Scurt FG; Menne JJ; Korda A; Haller H; Chatzikyrkou C
    J Diabetes; 2020 Nov; 12(11):856-859. PubMed ID: 32755046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of microalbuminuria in type 2 diabetes: lessons learned from the ROADMAP study.
    Ritz E; Menne J; Haller H
    Nephrol Dial Transplant; 2012 Dec; 27 Suppl 4():iv28-30. PubMed ID: 23258807
    [No Abstract]   [Full Text] [Related]  

  • 19. Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan.
    Abe M; Oikawa O; Okada K; Soma M
    J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):159-64. PubMed ID: 25287898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olmesartan for the prevention or delay of diabetic nephropathy: some considerations.
    Catalá-López F; Martín-Serrano G; Maciá MA; Montero D
    Rev Esp Cardiol (Engl Ed); 2012 Jul; 65(7):678-9; author reply 679-80. PubMed ID: 22608016
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.